<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053065</url>
  </required_header>
  <id_info>
    <org_study_id>MAPS</org_study_id>
    <nct_id>NCT01053065</nct_id>
  </id_info>
  <brief_title>The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study</brief_title>
  <acronym>MAPS</acronym>
  <official_title>The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Foundation for Cardiovascular Research of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact on cardiovascular events achieved by statin therapy seems to be mostly&#xD;
      attributable to the cholesterol-lowering effect with a highly debated contribution of the&#xD;
      lipid-independent pleiotropic effects. However, a short-term benefit has been documented for&#xD;
      patients treated with statins in acute coronary syndromes and other clinical settings. These&#xD;
      observations strengthened the hypothesis of additional, so-called pleiotropic actions of&#xD;
      statins.&#xD;
&#xD;
      The investigators therefore sought to investigate how different lipid-lowering strategies&#xD;
      (non-statin therapy, low-dose statin and high-dose statin) affects cellular composition of&#xD;
      carotid plaque over a short-term period of three months. Specifically the investigators tried&#xD;
      and dissect the LDL-C lowering impact on plaque cellular composition as compared to the&#xD;
      lipid-independent contribution on plaque macrophage and smooth muscle cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients (with Total Cholesterol (TC) ranging between 5.83-7.64 mmol/l), never treated with&#xD;
      lipid lowering drugs, with symptomatic carotid stenosis &gt;70% (NASCET criteria), and therefore&#xD;
      eligible for carotid endarterectomy, were recruited. All patients were enrolled within 30&#xD;
      days from the clinical event, and randomized to one of three treatment groups. Each group,&#xD;
      composed of 20 patients, received atorvastatin 10 mg/day (AT-10 group), or atorvastatin 80&#xD;
      mg/day (AT-80 group), or cholestyramine (Questran, Bristol Myer Squibb) 8 g/day plus&#xD;
      sitosterol (Unilever) 2.5 g/day (C-S group) for three months prior to the vascular procedure.&#xD;
      A placebo group was not included for ethical reasons due to the high cardiovascular risk&#xD;
      profile in this population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cellular composition of carotid plaque.</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Symptomatic Carotid Stenosis</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Indication for Carotid Endarterectomy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 10 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm composed of 20 patients, receiving atorvastatin 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm composed of 20 patients, receiving atorvastatin 80 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholestyramine - Sitosterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin - Cholestyramine - Sitosterol</intervention_name>
    <arm_group_label>Atorvastatin 10 mg/day</arm_group_label>
    <arm_group_label>Atorvastatin 80 mg/day</arm_group_label>
    <arm_group_label>Cholestyramine - Sitosterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic carotid stenosis &gt; 70% (NASCET criteria)&#xD;
&#xD;
          -  Eligibility for carotid endarterectomy&#xD;
&#xD;
          -  Total cholesterol level between 5.83 and 7.64 mmol/L&#xD;
&#xD;
          -  Never treated with lipid lowering drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous lipid lowering therapy&#xD;
&#xD;
          -  Total cholesterol &lt;5.83 or &gt;7.64 mmol/L&#xD;
&#xD;
          -  Evidence of chronic inflammatory disease (clinical and laboratory).&#xD;
&#xD;
          -  Patients at high risk for cerebrovascular events (i.e. ulcerated carotid plaque,&#xD;
             recurrent TIAs).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Pauletto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chieti Medical School</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova Medical School</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Padova Medical School - Treviso Branch</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Pauletto P, Puato M, Faggin E, Santipolo N, Pagliara V, Zoleo M, Deriu GP, Grego F, Plebani M, Sartore S, Bon GB, Heymes C, Samuel JL, Pessina AC. Specific cellular features of atheroma associated with development of neointima after carotid endarterectomy: the carotid atherosclerosis and restenosis study. Circulation. 2000 Aug 15;102(7):771-8.</citation>
    <PMID>10942746</PMID>
  </reference>
  <reference>
    <citation>Faggin E, Zambon A, Puato M, Deeb SS, Bertocco S, Sartore S, Crepaldi G, Pessina AC, Pauletto P. Association between the --514 C--&gt;T polymorphism of the hepatic lipase gene promoter and unstable carotid plaque in patients with severe carotid artery stenosis. J Am Coll Cardiol. 2002 Sep 18;40(6):1059-66.</citation>
    <PMID>12354428</PMID>
  </reference>
  <verification_date>January 2005</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <keyword>Atherosclerosis</keyword>
  <keyword>Macrophages</keyword>
  <keyword>Carotid arteries</keyword>
  <keyword>Statin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Cholestyramine Resin</mesh_term>
    <mesh_term>Gamma-sitosterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

